Cipla’s Pithampur unit receives 8 USFDA observations; stock tanks ~5%

20 Feb 2023 , 10:33 AM

Cipla stated that the US Food and Drug Administration (USFDA) issued Form 483 with eight observations after inspecting its Pithampur-based manufacturing facility in Madhya Pradesh.

The US Food and Drug Administration (USFDA) undertook a current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility from February 6 to 17, said Cipla in its regulatory filing.

The company further added that it received 8 inspectional observations in Form 483 at the end of the inspection.

According to the company, it will work closely with the USFDA and is committed to addressing these issues comprehensively within the time frame specified.

Following this development, Cipla stock was trading 4.94% lower at Rs975 per piece, against the previous close of Rs1,025.75 on NSE. The counter opened at Rs998 and touched an intraday low of Rs955.25 so far.

For feedback and suggestions, write to us at [e-mail]